MedTrace Logo

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

NCT04285866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2022-06-07

No results posted yet for this study

Summary

This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study.

The study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the real world. The patients participating in this non-interventional study will not receive treatment in relation to the study. The primary objective is to assess affectiveness of durvalumab in patients treated in real-life settings by evaluating Progression Free Survival.

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

DRUG

Durvalumab

Durvalumab after chemoradiotherapy

Sponsors & Collaborators

  • Fundación GECP

    lead OTHER

Principal Investigators

  • Pilar Garrido, MD · Fundación GECP Investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04285866 on ClinicalTrials.gov